Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease

Published:2018-12-15 Issue:24 Volume:57 Page:3651-3657
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kimura Satoshi¹,Ohkawara Hiroshi¹,Ogawa Kazuei¹,Tanaka Mizuko²,Sano Takahiro¹,Harada-Shirado Kayo¹,Takahashi Hiroshi¹,Ueda Koki¹,Shichishima-Nakamura Akiko¹,Matsumoto Hayato¹,Ikeda Kazuhiko³,Kazama Junichiro James⁴,Hashimoto Yuko²,Ikezoe Takayuki¹

Affiliation:

1. Department of Hematology, Fukushima Medical University, Japan

2. Department of Diagnostic Pathology, Fukushima Medical University, Japan

3. Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Japan

4. Department of Nephrology and Hypertension, Fukushima Medical University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/24/57_1018-18/_pdf

Reference36 articles.

1. 1. Sayed RH, Wechalekar AD, Gilbertson JA, et al. Natural history and outcome of light chain deposition disease. Blood 126: 2805-2810, 2015.

2. 2. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 22: 319-330, 2002.

3. 3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016.

4. 4. Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 1: 1342-1350, 2006.

5. 5. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 32: 17-24, 2008.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies;Annals of Hematology;2024-08-28

2. Treatment of Light Chain Deposition Disease: A Systematic Review;Journal of Hematology;2022-08

3. Case Report: Lenalidomide as a Second-Line Treatment for Bortezomib-Ineffective Nephrotic Syndrome Caused by LCDD: 2 Case Reports and a Literature Review;Frontiers in Medicine;2021-10-08

4. Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone;Renal Failure;2021-01-01

5. Remission of light chain proximal tubulopathy in IgG λ-type multiple myeloma by lenalidomide and dexamethasone therapy;CEN Case Reports;2019-02-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3